PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.56%
Revenue growth of 4.56% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
2.69%
Gross profit growth of 2.69% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
5.94%
Positive EBIT growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong competitive advantage in operations.
0.67%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
-4.69%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-4.70%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-4.70%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.03%
10Y CAGR of 7.03% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
-7.20%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 3.04%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-32.91%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.03%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-100.00%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is -5.90%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
No Data
No Data available this quarter, please select a different quarter.
24.45%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper issues limiting long-term profit growth.
15.10%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper problems limiting mid-term profit potential.
-43.23%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 27.53%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
No Data
No Data available this quarter, please select a different quarter.
33.35%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 11.92%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
-12.89%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
-100.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
-100.00%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-99.40%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
0.08%
Inventory reduction well below Medical - Pharmaceuticals median. Joel Greenblatt might see a sign of superior operational or supply-chain efficiency.
1.93%
We expand assets while Medical - Pharmaceuticals is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
4.20%
BV/share growth of 4.20% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-34.68%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
82.29%
SG&A growth of 82.29% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.